CA2561452A1 - Neuroprotective benzoate and benzamide compounds - Google Patents

Neuroprotective benzoate and benzamide compounds Download PDF

Info

Publication number
CA2561452A1
CA2561452A1 CA002561452A CA2561452A CA2561452A1 CA 2561452 A1 CA2561452 A1 CA 2561452A1 CA 002561452 A CA002561452 A CA 002561452A CA 2561452 A CA2561452 A CA 2561452A CA 2561452 A1 CA2561452 A1 CA 2561452A1
Authority
CA
Canada
Prior art keywords
alkyl
cycloalkyl
compound
procaine
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002561452A
Other languages
English (en)
French (fr)
Inventor
Laurent Lecanu
Janet Greeson
Vassilios Papadopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Samaritan Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2561452A1 publication Critical patent/CA2561452A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002561452A 2003-06-02 2004-05-20 Neuroprotective benzoate and benzamide compounds Abandoned CA2561452A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US47496403P 2003-06-02 2003-06-02
US60/474,964 2003-06-02
US47564203P 2003-06-04 2003-06-04
US60/475,642 2003-06-04
US47864803P 2003-08-01 2003-08-01
US60/478,648 2003-08-01
US56686904P 2004-04-30 2004-04-30
US60/566,869 2004-04-30
PCT/US2004/016036 WO2004108666A2 (en) 2003-06-02 2004-05-20 Neuroprotective benzoate and benzamide compounds

Publications (1)

Publication Number Publication Date
CA2561452A1 true CA2561452A1 (en) 2004-12-16

Family

ID=33514878

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002561452A Abandoned CA2561452A1 (en) 2003-06-02 2004-05-20 Neuroprotective benzoate and benzamide compounds

Country Status (6)

Country Link
US (2) US20060167108A1 (enExample)
EP (1) EP1628649A4 (enExample)
JP (1) JP2006526634A (enExample)
AU (1) AU2004245484A1 (enExample)
CA (1) CA2561452A1 (enExample)
WO (1) WO2004108666A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4949558B2 (ja) 1999-03-23 2012-06-13 ハイバーネーション・セラピューティクス・グローバル・リミテッド 臓器の停止、保護、及び保存
CA2559972A1 (en) * 2004-03-18 2005-09-29 Samaritan Pharmaceuticals, Inc. Benzamide and benzoate anti-hiv compounds
CN101022806A (zh) * 2004-04-15 2007-08-22 萨马里坦药品公司 （4－烷基哌嗪基）（苯基）甲酮在治疗阿尔茨海默病中的应用
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
KR101425579B1 (ko) 2006-05-29 2014-08-13 하이버네이션 테라퓨틱스 리미티드 개선된 조직 유지법
WO2008011670A1 (en) 2006-07-25 2008-01-31 Hibernation Therapeutics Limited Trauma therapy
US20100119554A1 (en) 2007-03-02 2010-05-13 Hibernation Therapeutics Limited Transplants
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
EP2219442A4 (en) * 2007-07-25 2012-05-02 Hibernation Therapeutics Ltd IMPROVED ORGAN PROTECTION, IMPROVED ORGAN CONSERVATION AND IMPROVED ORGAN RECOVERY
WO2014051398A1 (ko) * 2012-09-28 2014-04-03 한국생명공학연구원 아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
AU2014292827A1 (en) 2013-07-17 2016-02-04 Hibernation Therapeutics, A Kf Llc A method for organ arrest, protection and preservation and reducing tissue injury

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064858A (en) * 1988-08-17 1991-11-12 Spectrum Pharmaceutical Corporation Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and Alzheimer's disease
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
JPH1033087A (ja) * 1996-07-23 1998-02-10 Koichi Tanaka グルタミン酸トランスポーター遺伝子機能欠損非ヒト動物
JPWO2003035641A1 (ja) * 2001-10-22 2005-02-10 塩野義製薬株式会社 新規カルバモイルピロリドン誘導体

Also Published As

Publication number Publication date
US20090286876A1 (en) 2009-11-19
EP1628649A2 (en) 2006-03-01
AU2004245484A1 (en) 2004-12-16
US20060167108A1 (en) 2006-07-27
EP1628649A4 (en) 2010-06-02
WO2004108666A2 (en) 2004-12-16
WO2004108666A3 (en) 2005-03-31
JP2006526634A (ja) 2006-11-24
AU2004245484A2 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
US20090286876A1 (en) Neuroprotective benzoate and benzamide compounds
CN102781436B (zh) 纤维肌痛综合征的治疗方法
KR101785072B1 (ko) 하지 불안 증후군의 치료방법
WO2008097692A1 (en) Compounds, compositions and methods for the treatment of inflammatory diseases
EP3949953A1 (en) Sustained-release dosage forms of ruxolitinib
JP7045985B2 (ja) Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法
EP3630101B1 (en) Tegavivint for use in the treatment of pulmonary fibrosis
US20090197891A1 (en) Use of (4-Alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease
EP1358177B1 (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
CA3155805A1 (en) Phosphonium ion channel blockers and methods for use
CA2720987A1 (en) Dosages and methods for the treatment of cancer
CN106957315B (zh) N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
CA2720983A1 (en) Method of treating melanoma
JP2006526634A5 (enExample)
JPWO2005079845A1 (ja) 片頭痛予防薬
AU2019273656B2 (en) Pharmaceutical compounds for use in treating Huntington's disease
CA2559972A1 (en) Benzamide and benzoate anti-hiv compounds
US20250221964A1 (en) Substituted Isoxazoles as Selective Nav1.7 Inhibitors for Pain Treatment and Method of Pain Treatment
AU2024204318A1 (en) Treatment of Post-Traumatic Syndrome Disorder
WO2005016331A1 (ja) Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
CA2534777A1 (en) Sigma-1 receptor ligand with acetylcholinesterase inhibition properties
HK40068526A (en) Sustained-release dosage forms of ruxolitinib
JP2013525357A (ja) 多発性骨髄腫の治療のための組成物および方法
HK40000275A (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium
TH139656A (th) เอสเทอร์โพรดรักซ์-)Ester-Pro-drugs) ของ [3-(1-(1H-อิมิดาซอล-4-อิล(เอทธิล (-2-เมทธิลฟีนิล] เมทธานอลสำหรับการรักษาโรคผิวหนัง และสภาวะทางผิวหนัง

Legal Events

Date Code Title Description
FZDE Discontinued